{"id":1913,"date":"2025-10-21T08:09:27","date_gmt":"2025-10-21T08:09:27","guid":{"rendered":"https:\/\/network.rvrising.com\/?p=1913"},"modified":"2025-10-21T08:09:27","modified_gmt":"2025-10-21T08:09:27","slug":"legacy-spine-companies-retreat-while-kic-ventures-builds-new-markets-in-outpatient-interventional-spine-surgery-regenerative-biologics-and-viscoelastic-disc-replacements","status":"publish","type":"post","link":"https:\/\/www.rvrising.com\/news\/business\/legacy-spine-companies-retreat-while-kic-ventures-builds-new-markets-in-outpatient-interventional-spine-surgery-regenerative-biologics-and-viscoelastic-disc-replacements\/","title":{"rendered":"Legacy Spine Companies Retreat While KIC Ventures Builds New Markets in Outpatient Interventional Spine Surgery, Regenerative Biologics, and Viscoelastic Disc Replacements"},"content":{"rendered":"<p><span class=\"legendSpanClass\">FORT LAUDERDALE, Fla.<\/span>, <span class=\"legendSpanClass\">Oct. 15, 2025<\/span> \/PRNewswire\/ &#8212; As legacy spine and orthopedic companies divest from their core device portfolios and retreat from innovation, <b>Harvard-trained orthopedic spine surgeon and CEO Dr. Kingsley R. Chin<\/b> has demonstrated consistent leadership in guiding <b><a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4534299-1&amp;h=2356885933&amp;u=http%3A%2F%2Fwww.kicventures.com%2F&amp;a=KIC+Ventures\" target=\"_blank\" rel=\"nofollow noopener\">KIC Ventures<\/a><\/b> to advance a bold new vision \u2014 building sustainable global markets in <b>outpatient interventional spine surgery<\/b>, <b>regenerative biologics<\/b>, and <b>motion-preserving viscoelastic disc replacements<\/b>.<\/p>\n<p>KIC Ventures is defined by its <b>physician-led model<\/b>, featuring <b>Chief Medical Officer Dr. Erik Spayde<\/b>, a Harvard-trained orthopedic spine surgeon, and <b>Chief Technology Officer Vito Lore<\/b>, who has worked alongside Dr. Chin for over 15 years driving innovation in Less Exposure Spine Surgery (LESS) technologies. Supported by a <b>seasoned executive team<\/b> and a network of <b>physician investors<\/b> \u2014 many participating through <b>self-directed IRAs (SDIRAs)<\/b> via the <b><a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4534299-1&amp;h=3448370503&amp;u=https%3A%2F%2Fwww.iraclub.com%2Fpartner%2Fkicventures%2F&amp;a=IRA+Club\" target=\"_blank\" rel=\"nofollow noopener\">IRA Club<\/a><\/b> \u2014 KIC Ventures continues to lead where others have retreated.<\/p>\n<div>\n<p>The past decade has marked a wave of <b><a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4534299-1&amp;h=1435349403&amp;u=https%3A%2F%2Fwww.massdevice.com%2Fjohnson-johnson-separate-orthopedics-business%2F&amp;a=spine+industry+divestitures\" target=\"_blank\" rel=\"nofollow noopener\">spine industry divestitures<\/a><\/b>, as traditional giants exit innovation-heavy markets to consolidate and protect profits:<\/p>\n<ul type=\"disc\">\n<li><b>NuVasive<\/b>, the leader in lateral interbody cage fusion, was <b>assimilated into Globus<\/b> and effectively exited as an independent spine innovator.<\/li>\n<li><b>Biomet<\/b> was <b>acquired by Zimmer<\/b>, which later <b>divested its spine business into ZimVie<\/b>, and then <b>ZimVie was sold to Highbridge<\/b> \u2014 completing a full exit from spine.<\/li>\n<li><b>Stryker<\/b> <b>divested Stryker Spine<\/b>, walking away from decades of development.<\/li>\n<li><b>Integra<\/b> <b>divested SeaSpine<\/b>, another exit from spine.<\/li>\n<li><b>Aesculap<\/b> <b>divested its ActivL articulating disc replacement<\/b> program.<\/li>\n<li><b>DePuy Synthes<\/b> <b>divested its ProDisc<\/b> articulating disc replacement.<\/li>\n<li><b>Orthofix<\/b> <b>divested its M6 disc replacement<\/b> after widespread osteolysis concerns.<\/li>\n<\/ul>\n<p>These moves follow the <b>Vertiflex recall by Boston Scientific<\/b> and broader orthopedic restructuring at <b>Johnson &amp; Johnson<\/b>, signaling a systemic withdrawal from the innovation-intensive spine sector.<\/p>\n<p>&#8220;While others are exiting spine, we&#8217;re expanding it,&#8221; said <b>Dr. Kingsley R. Chin<\/b>, CEO and Founder of KIC Ventures. &#8220;We see what&#8217;s coming next \u2014 a shift to regenerative, motion-preserving, and outpatient treatments. Innovation doesn&#8217;t disappear; it migrates to those willing to lead.&#8221;<\/p>\n<ul type=\"disc\">\n<li><b> <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4534299-1&amp;h=1073064941&amp;u=http%3A%2F%2Fwww.axiomed.com%2F&amp;a=AxioMed\" target=\"_blank\" rel=\"nofollow noopener\">AxioMed<\/a> <\/b>\u00a0<b>Viscoelastic Disc Replacement<\/b> The only total disc replacement to complete a U.S. IDE study with <b>over 10 years of published outcomes<\/b>, AxioMed restores natural disc motion instead of eliminating it. Global commercialization is planned for <b>2026<\/b>, marking the new standard for motion preservation in spine.<\/li>\n<li><b>NanoFuse Biologics<\/b> Combining <b>synthetic 45S5 Bioactive Glass<\/b> with <b>demineralized bone matrix (DBM)<\/b>, NanoFuse delivers a <b>regenerative therapeutic platform<\/b> with a <b>five-year shelf life<\/b>. KIC Ventures is extending NanoFuse&#8217;s capabilities beyond bone regeneration into <b>therapeutic biologic applications<\/b>, positioning it as a next-generation <b>regenerative medicine solution<\/b>.<\/li>\n<li><b>ELID (Endoscopic Lumbar Intralaminar Decompression)<\/b> ELID represents a breakthrough in <b>endoscopic decompression<\/b>, enabling targeted intralaminar distraction and decompression for both spine surgeons and interventional pain specialists. Paired with <b>NANISX&#8217;s LESS Exposure Spine Surgery (LESS)<\/b> portfolio \u2014 <b>InSpan, FacetFuse, and Sacrix<\/b> \u2014 ELID anchors a <b>new interventional outpatient market<\/b>, moving spine surgery from the hospital to physician-owned ambulatory centers.<\/li>\n<\/ul>\n<p>&#8220;Cardiology evolved by shifting from open-heart surgery to interventional cardiology,&#8221; said <b>Dr. Chin<\/b>. &#8220;Spine is undergoing the same transformation. The future belongs to physician-led outpatient care \u2014 earlier treatment, preserved anatomy, and faster recovery. This is how real innovation scales.&#8221;<\/p>\n<p><b>Dr. Erik Spayde<\/b>, CMO and Harvard-trained orthopedic spine surgeon, highlighted the physician-led foundation:<\/p>\n<p>&#8220;Our clinical insight drives our innovation. We know where the bottlenecks are because we&#8217;ve lived them. That&#8217;s why our solutions are practical, evidence-based, and built to last.&#8221;<\/p>\n<p><b>Vito Lore<\/b>, CTO, reinforced KIC Ventures&#8217; product philosophy:<\/p>\n<p>&#8220;Our innovation strategy is guided by our <b>LESS treatment philosophy \u2014 Less Exposure Spine Surgery<\/b>. We build best-in-class technologies that deliver superior outcomes with less trauma, less cost, and less complexity.&#8221;<\/p>\n<p><b>Aditya Humad<\/b>, President and CFO, emphasized the company&#8217;s physician-investor model:<\/p>\n<p>&#8220;Our investors are doctors who understand the clinical and economic value of what we&#8217;re building. Through partnerships with the <b>IRA Club<\/b>, many have invested using tax-free retirement capital via SDIRAs \u2014 turning their savings into ownership in the future of spine.&#8221;<\/p>\n<p>Every KIC Ventures technology is supported by <b>peer-reviewed research<\/b> published in top spine and orthopedic journals. Through the <b>LESS Society VET Tour<\/b>, KIC Ventures and its physician faculty are <b>training surgeons globally<\/b> to achieve standardized competency in interventional and outpatient spine techniques.<\/p>\n<p>Join us and invest.<\/p>\n<p>Visit the website:\u00a0<a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4534299-1&amp;h=1070594650&amp;u=http%3A%2F%2Fwww.kicventures.com%2F&amp;a=www.KICVentures.com\" target=\"_blank\" rel=\"nofollow noopener\">www.KICVentures.com<\/a> or call us at +1(855)411-LESS<\/p>\n<p><b>KIC Ventures<\/b> is a physician-founded private equity healthtech group driving innovation in spine and orthopedics. Guided by the <b>REP principles \u2014 Restore Function, Early Intervention, Preserve Anatomy<\/b>, KIC Ventures acquires, develops, and commercializes technologies that transition spine care from hospital-based fusion to regenerative, motion-preserving, and outpatient solutions.<\/p>\n<p>The KIC Ventures portfolio includes <b>AxioMed<\/b>, <b>NanoFuse Biologics<\/b>, and <b>NANISX<\/b>, each advancing the next generation of <b>Interventional Spine Surgery<\/b> and <b>Regenerative Therapeutics<\/b> worldwide.<\/p>\n<p>SOURCE KIC Ventures<img decoding=\"async\" style=\"border: 0px; width: 1px; height: 1px;\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=NE99418&amp;Transmission_Id=202510152110PR_NEWS_USPR_____NE99418&amp;DateId=20251015\" alt=\"\" \/><\/p>\n<\/div>\n<p><b>This release is auto-published via PR Newswire; our journal is not responsible for the content.<\/b><\/p>\n<p><a href=\"https:\/\/www.prnewswire.com\/news-releases\/legacy-spine-companies-retreat-while-kic-ventures-builds-new-markets-in-outpatient-interventional-spine-surgery-regenerative-biologics-and-viscoelastic-disc-replacements-302585615.html\">Source link <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>FORT LAUDERDALE, Fla., Oct. 15, 2025 \/PRNewswire\/ &#8212; As legacy spine and orthopedic companies divest from their core<\/p>\n","protected":false},"author":1,"featured_media":1914,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[8,92],"tags":[552],"class_list":["post-1913","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business","category-pr-newswire","tag-kic-ventures"],"_links":{"self":[{"href":"https:\/\/www.rvrising.com\/news\/wp-json\/wp\/v2\/posts\/1913","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.rvrising.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.rvrising.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.rvrising.com\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.rvrising.com\/news\/wp-json\/wp\/v2\/comments?post=1913"}],"version-history":[{"count":1,"href":"https:\/\/www.rvrising.com\/news\/wp-json\/wp\/v2\/posts\/1913\/revisions"}],"predecessor-version":[{"id":2296,"href":"https:\/\/www.rvrising.com\/news\/wp-json\/wp\/v2\/posts\/1913\/revisions\/2296"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.rvrising.com\/news\/wp-json\/wp\/v2\/media\/1914"}],"wp:attachment":[{"href":"https:\/\/www.rvrising.com\/news\/wp-json\/wp\/v2\/media?parent=1913"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.rvrising.com\/news\/wp-json\/wp\/v2\/categories?post=1913"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.rvrising.com\/news\/wp-json\/wp\/v2\/tags?post=1913"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}